News Industry News Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) September 20, 2016
News Industry News FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor July 11, 2016
News Industry News Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol January 21, 2016
News Industry News European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol July 21, 2015
News Industry News Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab August 25, 2014
News Industry News Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia July 30, 2014